🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Cristina Guarducci

Harvard University

ORCID: 0000-0002-3234-564X

Also affiliated with Dana-Farber Cancer Institute, Hospital of Prato

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer”.

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Cancer Research(2023)10.1158/0008-5472.can-23-1711

N/A

0.596DataRank · unranked

15 citations

Yingtian Xie, Shira Sherman, Zsuzsanna Nagy, Douglas Russo, Tara Akhshi +36 more

Combination of fulvestrant and chemotherapy in ESR1 Y537S mutant breast cancer cells and potential synergy mechanism related to p53 wildtype.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1065

N/A

0.104DataRank · unranked

1 citations

Francisco Hermida‐Prado, Cristina Guarducci, Avery Feit, Agostina Nardone, Gabriella Cohen +6 more

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.29.486217

N/A

0DataRank · unranked

1 citations

Xintao Qiu, Ariel Feiglin, Xiaoyong Fu, Sándor Spisák, Avery Feit +20 more

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0257

N/A

0DataRank · unranked

11 citations

Shayna Stein, Agostina Nardone, Weihan Liu, Wen Ma, Gabriella Cohen +5 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603

N/A

0DataRank · unranked

0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603.v1

N/A

0DataRank · unranked

0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2975

N/A

0DataRank · unranked

35 citations

Agostina Nardone, Douglas Russo, Zsuzsanna Nagy, Capucine Héraud, Albert Grinshpun +26 more

Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer

npj Breast Cancer(2024)10.1038/s41523-024-00647-1

N/A

0DataRank · unranked

4 citations

Douglas Russo, Wen Ma, Ana Verma, Francisco Hermida-Prado, Shira Sherman +13 more

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-19-4191

N/A

0DataRank · unranked

94 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more